valsartan has been researched along with diethylnitrosamine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, AA; Buha, SK; Charoo, NA; Rahman, Z | 1 |
| Abdel-Tawab, M; Besa, A; Bidmon, C; Ermel, S; Holzgrabe, U; Kinzig, M; Scherf-Clavel, O; Schreiber, A; Sörgel, F; Wohlfart, J | 1 |
| Schmidt, AH; Schmidtsdorff, S | 1 |
| Al-Kindi, SG; Oliveira, GH | 1 |
4 other study(ies) available for valsartan and diethylnitrosamine
| Article | Year |
|---|---|
Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Topics: Angiotensin II Type 1 Receptor Blockers; Diethylnitrosamine; Dimethylnitrosamine; Drug Compounding; Drug Contamination; Drug Industry; Drug Recalls; Humans; Mutagens; Patient Safety; United States; United States Food and Drug Administration; Valsartan | 2019 |
The contamination of valsartan and other sartans, part 1: New findings.
Topics: China; Chromatography, Liquid; Diethylnitrosamine; Dimethylnitrosamine; Drug Contamination; Gas Chromatography-Mass Spectrometry; Nitrosamines; Tandem Mass Spectrometry; Valsartan; Water Pollutants, Chemical | 2019 |
Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
Topics: Angiotensin II Type 1 Receptor Blockers; Chromatography, Supercritical Fluid; Diethylnitrosamine; Dimethylnitrosamine; Drug Contamination; Limit of Detection; Losartan; Nitrosamines; Propylamines; Quality Control; Reference Standards; Risk Assessment; Valsartan | 2019 |
Abrupt Increase in Reporting of Neoplasms Associated with Valsartan After Medication Recall.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin II Type 1 Receptor Blockers; Carcinogens; Diethylnitrosamine; Drug Contamination; Drug Recalls; Humans; Neoplasms; Patient Safety; Risk Assessment; Risk Factors; Time Factors; Valsartan | 2019 |